The Research of the application of a new Urinary Biomarker PCA-M of Prostate Cancer (PSA from 4 to 20 ng/ml)

<strong>Background</strong><b>:</b> To evaluate the diagnostic effects of urine PCA-M (prostate cancer antigen -methylation) DNA level in patients with PSA from 4 to 20 ng/ml. <b>Methods: </b>We first explored the diagnostic value of PCAM (<i>PRKY</i> and <i>TGIF2LY</i>) based on prostate cancer samples from the TCGA database. Then ninety-five patients with PSA concentration of 4-20 ng/ml were collected as subjects. The level of urinary PCA-M DNA was detected by RT-PCR. The sensitivity and specificity of the diagnosis and the AUC were calculated and compared with f/t PSA, PSAD. <b>Results: </b>Bioinformatics analysis showed that the expression of <i>PRKY</i> in prostate cancer tissues was significantly higher than that in adjacent normal tissues, while the expression of <i>TGIF2LY</i> in normal prostate tissues was significantly higher than that in cancer tissues (<i>P</i>&lt;0.001). The results of RT-PCR showed that the level of urinary PCA-M protein kinase <i>PRKY</i> in patients diagnosed with PCA (<i>P</i>&lt;0.0001), while the level of urinary <i>TGIF2LY</i> in patients with PCA was on the contrary. The AUC value of urinary <i>PRKY</i> level was the highest compared with urinary <i>TGIF2LY</i>, f / tPSA and PSAD. <b>Conclusions: </b>PCA-M could be a biomarker for diagnosing patients with PSA from 4 to 20 ng/ml.